By Josh White
Date: Thursday 19 Mar 2026
(Sharecast News) - GSK said on Thursday that the US Food and Drug Administration has approved its drug 'Lynavoy', or linerixibat, for the treatment of cholestatic pruritus in adults with primary biliary cholangitis, marking the first approved therapy in the US for the condition.
| Ofcom to oversee final phase of full-fibre rollout | 17-Mar-2026 | ShareCast |
| FDA expands approved age indication for GSK RSV ... | 13-Mar-2026 | ShareCast |
| Computacenter hails 'outstanding' year for NA as... | 12-Mar-2026 | ShareCast |
| Transaction in Own Shares | 10-Mar-2026 | ShareCast |
| Transaction in Own Shares | 10-Mar-2026 | ShareCast |
| Transaction in Own Shares | 20-Mar-2026 | 13:52 | RNS |
| Dealing Disclosure under Rule 8 Takeover Code | 20-Mar-2026 | 13:50 | RNS |
| Dealing Disclosure under Rule 8 Takeover Code | 20-Mar-2026 | 13:49 | RNS |
| Form 8.3 NCC GROUP PLC | 20-Mar-2026 | 13:43 | RNS |
| Director/PDMR Shareholding | 20-Mar-2026 | 13:42 | RNS |
| Questor:Meggitt | 23-Dec-2014 | Telegraph |
| Questor :KCOM | 27-Nov-2014 | Telegraph |
| Questor :Ricardo | 31-Oct-2014 | Telegraph |
| Questor:CSR | 17-Oct-2014 | Telegraph |
| Questor:BAE Systems | 03-Sep-2014 | Telegraph |
| Price | 5,711.16 |
| Change Today | -8.86 |
| % Change | -0.15 % |
| 19-Mar-26 Close | 5,720.02 |
You are here: research